76343-93-6|Latrunculin A(solution)，≥98%|Medlife|Medlife为MCE，Selleck，麦克林，阿拉丁试剂，罗恩试剂，Sigma，安耐吉试剂，泰坦等同类产品品牌，上海现货，高性价比小分子化合物

您当前的位置：

Latrunculin A(solution)

可逆的肌动蛋白装配抑制剂，Latrunculin A (LAT-A) 是从红海海绵 Latrunculia magnifica 中得到的一种毒素，能够与肌动蛋白 (actin) 单体结合，抑制肌动蛋白聚集，对 ATP-actin，ADP-Pi-actin，ADP-actin 和 G-actin 的 Kd 值分别为 0.1，0.4，4.7 μM 和 0.19 μM。

目录号: PC15250 纯度: ≥98%

CAS No. :76343-93-6

商品编号	规格	价格	会员价	是否有货	数量
PC15250-50ug (solution)	50ug(solution)	¥1950.00	请登录
PC15250-100ug (solution)	100ug(solution)	¥2836.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Latrunculin A(solution)
中文别名	红海海绵素A;微丝解聚剂;红海海绵素 A
英文名称	Latrunculin A(solution)
英文别名	2-Thiazolidinone,4-[(1R,4Z,8E,10Z,12S,15R,17R)-17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17-yl]-,(4R)-;(4R)-4-[(1R,4S,5Z,7E,11Z,15R,17R)-17-hydroxy-4,11-dimethyl-13-oxo-14,18-dioxabicyclo[13.3.1]nonadeca-5,7,11-trien-17-yl]-1,3-thiazolidin-2-one;2-Thiazolidinone,4-[(1R,4Z,8E,10Z,12S,15R,17R)-17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-;LAPPACONITINE;Latrunculin A (LAT-A,NSC 613011);LATRUNCULINA;2-Thiazolidinone,4-((1R,4Z,8E,10Z,12S,15R,17R)-17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo(13.3.1)nonadeca-4,8,10-trien-17-yl)-,(4R);LAT-A;latruculin A;latrunculin-A;[1R-[1R, 4Z, 8E, 10Z, 12S, 15R, 17R(R*)]]-4-(17-Hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17-yl)-2-thiazolidinone;Latrunculin;NSC 613011
Cas No.	76343-93-6
分子式	C₂₂H₃₁NO₅S
分子量	421.55
包装储存	Solution, -20°C, 2 years

生物活性

Latrunculin A (LAT-A), found in the red sea sponge Latrunculia magnifica, is a G-actin polymerization inhibitor. Latrunculin A binds to actin monomers and inhibits polymerization of actin with K_ds of 0.1, 0.4, 4.7 μM and 0.19 μM for ATP-actin, ADP-Pi-actin, ADP-actin and G-actin, respectively. Latrunculin A has effective anti-metastatic properties for cancer research. Latrunculin A blocks cell migration.

性状

Liquid

IC50 & Target[1][2]

Kd: 0.1 μM (ATP-actin), 0.4 μM (ADP-Pi-actin), 4.7 μM (ADP-actin), 0.19 μM (G-actin)

体外研究(In Vitro)

Latrunculin A (50-1000 nM) exhibits potent anti-invasive activity against human prostate cancer PC-3M cells, inhibits PC-3M-CT+ spheroids disaggregation and cell migration.
Latrunculin A (3-30 μM) inhibits hypoxia-induced HIF-1 activation with an IC₅₀ value of 6.7 μM in human breast carcinoma T47D cells.
Latrunculin A (0-0.2 μM, 4 hours) has a significant inhibitory effect on HuR levels at high concentrations such as 0.2 μM in human hepatoma HepG2 cells while inhibits HuR only at 0.02 μM but no inhibitory effect at high concentrations in human hepatoma Huh7 cells.
Latrunculin A (0.1 μM, 24 hours) can lead to a significant decrease in cell migration and has an inhibitory effect on cell proliferation in human hepatoma cell lines HepG2.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Latrunculin A (intraperitoneal injection, 0.05 mg/kg, three doses in the first 20 days, 120 days) has strong antitumor effect in male BALB/c nude mice models infected with adenocarcinoma (MKN45) or carcinoma (NUGC-4).

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BALB/c nude mice models infected with adenocarcinoma (MKN45) or carcinoma (NUGC-4)
Dosage:	0.05 mg/kg
Administration:	Intraperitoneal injection; three doses in the first 20 days; 120 days
Result:	Extended the mean life expectancy to 23.5 days comparing to control of 16 days in adenocarcinoma (MKN45) mice and the mean survival time was 42 days comparing to untreated of 31 days in carcinoma (NUGC-4) mice.